Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on October 31st, 2022% 
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger
By Alan, on January 26th, 2022% 
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger
By Alan, on October 4th, 2021% 
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger
By Alan, on August 11th, 2021% 
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger
By Alan, on May 11th, 2021% 
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger
By Alan, on April 22nd, 2021% 
Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO
By Alan, on February 4th, 2021% 
A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO
By Alan, on January 18th, 2021% 
Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling
By Alan, on December 11th, 2020%
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO
By Alan, on November 3rd, 2020% 
Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
Comments are closed 
RSS - Posts
You must be logged in to post a comment.